Creative Medical Technology Holdings (CELZ) Change in Account Payables (2010 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Change in Account Payables of $22767.0 for Q1 2026, up 1802.84% year-over-year from $1196.5 in Q1 2025, and down 3.24% quarter-over-quarter from $23529.0 in Q4 2025.
Creative Medical Technology Holdings (CELZ) Change in Account Payables (2010 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Change in Account Payables for 17 consecutive years, with $22767.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 1802.84% year-over-year to $22767.0; the TTM figure through Mar 2026 stood at $21262.0 (up 132.84% YoY), while the FY2025 annual figure was -$2842.0, up 93.52% from the prior year.
- Change in Account Payables slipped to $22767.0 in Q1 2026 per CELZ's latest filing, from $23529.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.9 million in Q4 2022 and bottomed at -$2.9 million in Q1 2023.
- Historically, Change in Account Payables has averaged -$27559.2 across 5 years, with a median of -$8743.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Account Payables slumped 8453.21% — and 2025, when it soared 6564.01%.
- Creative Medical Technology Holdings' Change in Account Payables stood at $2.9 million in 2022, then sank by 101.69% to -$49765.0 in 2023, then surged by 99.27% to -$364.0 in 2024, then jumped by 6564.01% to $23529.0 in 2025, then dropped by 3.24% to $22767.0 in 2026.
- Business Quant data shows CELZ's Change in Account Payables at $22767.0 in Q1 2026, $23529.0 in Q4 2025, and -$16291.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Creative Medical Technology Holdings | 1.88 Mn | 1.88 Mn | - | -16,218.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16,218.00 |
| Jun 30, 2026 | -16,218.00 |
| Mar 31, 2026 | 22,767.00 |
| Mar 31, 2026 | 22,767.00 |
| Dec 31, 2025 | 23,529.00 |
| Dec 31, 2025 | 23,529.00 |
| Sep 30, 2025 | -16,291.00 |
| Sep 30, 2025 | -16,291.00 |
| Jun 30, 2025 | -8,743.00 |
| Jun 30, 2025 | -8,743.00 |
| Mar 31, 2025 | -1,337.00 |
| Mar 31, 2025 | -1,337.00 |
| Dec 31, 2024 | -364.00 |
| Dec 31, 2024 | -364.00 |
| Sep 30, 2024 | -48,364.00 |
| Sep 30, 2024 | -48,364.00 |
| Jun 30, 2024 | -14,687.00 |
| Jun 30, 2024 | -14,687.00 |
| Mar 31, 2024 | 19,565.00 |
| Mar 31, 2024 | 19,565.00 |